These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38697850)

  • 1. Longitudinal Comparative Analysis of Circulating Tumor DNA and Matched Tumor Tissue DNA in Patients with Metastatic Colorectal Cancer Receiving Palliative First-Line Systemic Anti-Cancer Therapy.
    Lee SB; Kim JW; Kim HG; Hwang SH; Kim KJ; Lee JH; Seo J; Kang M; Jung EH; Suh KJ; Kim SH; Kim JW; Kim YJ; Kim JH; Kwon NJ; Lee KW
    Cancer Res Treat; 2024 Oct; 56(4):1171-1182. PubMed ID: 38697850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR.
    Lim Y; Kim S; Kang JK; Kim HP; Jang H; Han H; Kim H; Kim MJ; Lee KH; Ryoo SB; Park JW; Jeong SY; Park KJ; Kang GH; Han SW; Kim TY
    Sci Rep; 2021 Aug; 11(1):16333. PubMed ID: 34381078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
    Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
    Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
    [No Abstract]   [Full Text] [Related]  

  • 4. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
    Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporal dynamics of RAS mutations in circulating tumor DNA in metastatic colorectal cancer: clinical significance of mutation loss during treatment.
    Iguchi K; Shiozawa M; Uchiyama M; Asari M; Numata K; Rino Y; Saito A
    J Cancer Res Clin Oncol; 2024 May; 150(5):281. PubMed ID: 38805050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer.
    Lee DW; Lim Y; Kim HP; Kim SY; Roh H; Kang JK; Lee KH; Kim MJ; Ryoo SB; Park JW; Jeong SY; Park KJ; Kang GH; Han SW; Kim TY
    Cancer Res Treat; 2023 Jul; 55(3):927-938. PubMed ID: 36915247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
    Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
    J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.
    Thierry AR; El Messaoudi S; Mollevi C; Raoul JL; Guimbaud R; Pezet D; Artru P; Assenat E; Borg C; Mathonnet M; De La Fouchardière C; Bouché O; Gavoille C; Fiess C; Auzemery B; Meddeb R; Lopez-Crapez E; Sanchez C; Pastor B; Ychou M
    Ann Oncol; 2017 Sep; 28(9):2149-2159. PubMed ID: 28911069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis.
    Kim S; Cha Y; Lim Y; Roh H; Kang JK; Lee KH; Kim MJ; Park JW; Ryoo SB; Kim HP; Jeong SY; Park KJ; Han SW; Kim TY
    Int J Cancer; 2023 Aug; 153(3):571-583. PubMed ID: 37194418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of circulating tumor DNA by tumor-informed whole-genome sequencing enables prediction of recurrence in stage III colorectal cancer patients.
    Frydendahl A; Nors J; Rasmussen MH; Henriksen TV; Nesic M; Reinert T; Afterman D; Lauterman T; Kuzman M; Gonzalez S; Glavas D; Smadback J; Maloney D; Levativ J; Yahalom M; Ptashkin R; Tavassoly I; Donenhirsh Z; White E; Kandasamy R; Alon U; Nordentoft I; Lindskrog SV; Dyrskjøt L; Jaensch C; Løve US; Andersen PV; Thorlacius-Ussing O; Iversen LH; Gotschalck KA; Zviran A; Oklander B; Andersen CL
    Eur J Cancer; 2024 Nov; 211():114314. PubMed ID: 39316995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
    Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
    Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer.
    Wang W; Huang Y; Kong J; Lu L; Liao Q; Zhu J; Wang T; Yan L; Dai M; Chen Z; You J
    Clin Transl Oncol; 2024 Aug; 26(8):1976-1987. PubMed ID: 38777950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.
    Morelli MP; Overman MJ; Dasari A; Kazmi SMA; Mazard T; Vilar E; Morris VK; Lee MS; Herron D; Eng C; Morris J; Kee BK; Janku F; Deaton FL; Garrett C; Maru D; Diehl F; Angenendt P; Kopetz S
    Ann Oncol; 2015 Apr; 26(4):731-736. PubMed ID: 25628445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical value of sequential circulating tumor DNA analysis using next-generation sequencing and epigenetic modifications for guiding thermal ablation for colorectal cancer metastases: a prospective study.
    Boeken T; Pellerin O; Bourreau C; Palle J; Gallois C; Zaanan A; Taieb J; Lahlou W; Di Gaeta A; Al Ahmar M; Guerra X; Dean C; Laurent Puig P; Sapoval M; Pereira H; Blons H
    Radiol Med; 2024 Oct; 129(10):1530-1542. PubMed ID: 39183242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer.
    Osumi H; Shinozaki E; Takeda Y; Wakatsuki T; Ichimura T; Saiura A; Yamaguchi K; Takahashi S; Noda T; Zembutsu H
    Cancer Med; 2019 Jan; 8(1):408-417. PubMed ID: 30575318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Advanced Biliary Tract Cancer.
    Chen C; Wang T; Yang M; Song J; Huang M; Bai Y; Su H
    Pathol Oncol Res; 2021; 27():1609879. PubMed ID: 34720757
    [No Abstract]   [Full Text] [Related]  

  • 17. Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer.
    Max Ma X; Bendell JC; Hurwitz HI; Ju C; Lee JJ; Lovejoy A; Mancao C; Nicholas A; Price R; Sommer N; Tikoo N; Yao L; Yaung SJ; Palma JF
    Clin Cancer Res; 2020 Aug; 26(15):4010-4017. PubMed ID: 32220893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.
    Montagut C; Argilés G; Ciardiello F; Poulsen TT; Dienstmann R; Kragh M; Kopetz S; Lindsted T; Ding C; Vidal J; Clausell-Tormos J; Siravegna G; Sánchez-Martín FJ; Koefoed K; Pedersen MW; Grandal MM; Dvorkin M; Wyrwicz L; Rovira A; Cubillo A; Salazar R; Desseigne F; Nadal C; Albanell J; Zagonel V; Siena S; Fumi G; Rospo G; Nadler P; Horak ID; Bardelli A; Tabernero J
    JAMA Oncol; 2018 Apr; 4(4):e175245. PubMed ID: 29423521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.
    van Helden EJ; Angus L; Menke-van der Houven van Oordt CW; Heideman DAM; Boon E; van Es SC; Radema SA; van Herpen CML; de Groot DJA; de Vries EGE; Jansen MPHM; Sleijfer S; Verheul HMW
    Mol Oncol; 2019 Nov; 13(11):2361-2374. PubMed ID: 31350822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer.
    Jia N; Chang L; Gao X; Shi X; Dou X; Guan M; Shao Y; Li N; Cheng Y; Ying H; Sun Z; Zhou Y; Zhao L; Zhou J; Bai C
    BMC Cancer; 2021 Jul; 21(1):845. PubMed ID: 34294055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.